electroCore - ECOR Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for electroCore in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ECOR shares.
View ECOR analyst ratings or view top-rated stocks.

4 brokers have issued 1 year price targets for electroCore's shares. Their ECOR share price forecasts range from $1.50 to $330.00. On average, they anticipate the company's stock price to reach $165.75 in the next twelve months. This suggests a possible upside of 44,697.3% from the stock's current price.
View analysts price targets for ECOR or view top-rated stocks among Wall Street analysts.

electroCore's stock was trading at $0.2568 at the beginning of the year. Since then, ECOR stock has increased by 44.1% and is now trading at $0.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our ECOR earnings forecast.

electroCore, Inc. (NASDAQ:ECOR) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm earned $1.49 million during the quarter, compared to analysts' expectations of $1.58 million. electroCore had a negative net margin of 283.41% and a negative trailing twelve-month return on equity of 72.36%. During the same quarter last year, the business posted ($0.10) EPS.

electroCore updated its fourth quarter 2022 earnings guidance on Tuesday, January, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.50 million-$2.50 million, compared to the consensus revenue estimate of $2.17 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other electroCore investors own include T2 Biosystems (TTOO), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Acasti Pharma (ACST), Onconova Therapeutics (ONTX) and OPKO Health (OPK).

(ECOR) raised $64 million in an IPO on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.

electroCore trades on the NASDAQ under the ticker symbol "ECOR."

electroCore's stock is owned by a number of institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.49%). Insiders that own company stock include Brian M Posner, Daniel S Goldberger, John P Gandolfo, Joseph P Errico, Thomas J Errico, Thomas J Errico and Trevor J Moody.
View institutional ownership trends.

Shares of ECOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ECOR stock can currently be purchased for approximately $0.37.

electroCore (NASDAQ:ECOR) has a market capitalization of $26.33 million and generates $5.45 million in revenue each year. The company earns $-17,220,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

electroCore's mailing address is 150 ALLEN ROAD SUITE 201, BASKING RIDGE NJ, 07920. The official website for the company is www.electrocore.com. The company can be reached via phone at (973) 290-0097 or via email at investors@electrocore.com.